重组人血管内皮抑制素联合多西他赛和顺铂方案新辅助化疗治疗晚期上皮性卵巢癌的临床疗效观察

doi:10.3760/cma.j.issn.1674-6090.2018.02.017

科研成果详情

题名	重组人血管内皮抑制素联合多西他赛和顺铂方案新辅助化疗治疗晚期上皮性卵巢癌的临床疗效观察
其他题名	Clinical research of neoadjuvant chemotherapy of endostar combined with TP for patients with advanced ovarian cancer
作者	李苏霞; 林蓓蓓; 陈素秀
发表日期	2018-04-25
发表期刊	中华内分泌外科杂志影响因子和分区
语种	中文
原始文献类型	学术期刊
关键词	晚期卵巢癌重组人血管内皮抑制素新辅助化疗预后
其他关键词	Advanced ovarian cancer ; Endostatin ; Neoadjuvant chemotherapy ; Prognosis
摘要	目的探讨重组人血管内皮抑制素(endostatin,ES)联合多西他赛和顺铂方案新辅助化疗治疗晚期上皮性卵巢癌的临床疗效。方法将2012年4月至2014年4月浙江温州医科大学附属第一医院的晚期卵巢癌患者76例用随机数字表法分为观察组和对照组,术前均行新辅助化疗,对照组采用多西他赛和顺铂(TP)方案,观察组采用ES联合TP方案。比较2组临床疗效、手术及远期生存情况。结果所有研究对象均顺利完成3个周期化疗,观察组白细胞下降程度、食欲减退、发热发生率均高于对照组,2组比较差异有统计学意义(P<0.05);所有研究对象在化疗后CA125、肿瘤负荷和腹腔积液深度均出现明显下降,化疗前后差异均有统计学意义(P<0.05);组在术中腹水量、出血量、手术时间、住院天数比较差异无统计学意义(P>0.05)。观察组残留病灶大小≤2 cm占比为84.2%,明显高于对照组的60.5%,且2者差异有统计学意义(P<0.05)。对照组和观察组1、3年总生存率分别为84.2%、63.1%和86.8、60.5%;2组总生存率差异无统计学意义(γ~2=0.207,P=0.649),对照组和观察组1、3年无疾病进展生存时间分别为89.4%、68.4%和94.7%、76.3%,2组无疾病进展生存率比较差异有统计学意义(γ~2=4.042,P=0.040)。结论 ES联合TP方案治疗晚期卵巢癌是安全有效的,可提高肿瘤减灭术切净率,提高肿瘤局部控制率。
其他摘要	Objective To explore the clinical effect of neoadjuvant chemotherapy of endostar combined with docetaxel plus cisplatin(TP) on patients with advanced ovarian cancer.Methods 76 patients meeting the criterion were enrolled to the study,and they were randomly divided into study group and the control group.The control group were administered with TP,while the study group received endostar combined with TP.The clinical effects,conditions of surgery and long-term survival were observed.Results All patients finished 3 cycles of neoadjuvant chemotherapy.The incidence of adverse reactions (leucopenia,anorexia and fever) in the study group was higher than that in the control group,and the difference had statistical significance (P＜0.05).The level of CA125,tumor load and ascites volume decreased after chemotherapy (P＜0.05).The two groups had no significance difference in intraoperative ascites,blood loss,time of surgery or hospital stay (P＞0.05).The rate of residual lesion≤2 cm was 84.2％ in the study group,higher than that of the control group (60.5％),and the difference had statistical significance (P＜0.05).The overall 1-year and 3-year survival were 84.2％,and 63.1％ for the control group,86.8％ and 60.5％ for the study group,and the difference had no statistical significance (γ2=0.207,P=0.649).One-year and 3-year disease free survival were 89.4％ and 68.4％ for the control group,94.7％ and 76.3％ for the study group (γ2=4.042,P=0.040).Conclusion Endostar combined with TP (docetaxel plus cisplatin) for patients with advanced ovarian cancer is safe and effective,which can improve the success rate of cytoreductive surgery and local control rate of tumor.
ISSN	1674-6090
卷号	12 期号:02 页码:158-162
DOI	10.3760/cma.j.issn.1674-6090.2018.02.017
页数	5
收录类别	CNKI ; 万方 ; 维普 ; ISTIC
URL	查看原文
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/47100
专题	附属第一医院_全科医学科
作者单位	浙江省温州医科大学附属第一医院全科医学科
第一作者单位	附属第一医院_全科医学科
第一作者的第一单位	附属第一医院_全科医学科
推荐引用方式 GB/T 7714	李苏霞,林蓓蓓,陈素秀. 重组人血管内皮抑制素联合多西他赛和顺铂方案新辅助化疗治疗晚期上皮性卵巢癌的临床疗效观察[J]. 中华内分泌外科杂志,2018,12(02):158-162.
APA	李苏霞, 林蓓蓓, & 陈素秀. (2018). 重组人血管内皮抑制素联合多西他赛和顺铂方案新辅助化疗治疗晚期上皮性卵巢癌的临床疗效观察. 中华内分泌外科杂志, 12(02), 158-162.
MLA	李苏霞,et al."重组人血管内皮抑制素联合多西他赛和顺铂方案新辅助化疗治疗晚期上皮性卵巢癌的临床疗效观察".中华内分泌外科杂志 12.02(2018):158-162.